Review



ivermectin  (Valiant Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Valiant Co Ltd ivermectin
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Ivermectin, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/bio_rxiv__64898__2026__02__12__705610-117-5-6
    Average 94 stars, based on 7 article reviews
    ivermectin - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs"

    Article Title: Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs

    Journal: bioRxiv

    doi: 10.64898/2026.02.12.705610

    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with ivermectin (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Figure Legend Snippet: (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with ivermectin (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Techniques Used: Clinical Proteomics, CellTox Assay, Fluorescence, Staining, Control

    (A) Schematic showing methodology and timeline for mf temperature shift assay. (B) Mean motility, scaled to DMSO 1 hour values of B. pahangi mf at 37℃ (left panel) and room temperature (RT, right panel) across time and ivermectin (IVM) or control treatment concentrations (color-coded). P-values represent statistical differences in mf motility between DMSO and drug treatments at matched time points and temperature and were calculated using Anova/Tukey post-test and significance reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least six technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Figure Legend Snippet: (A) Schematic showing methodology and timeline for mf temperature shift assay. (B) Mean motility, scaled to DMSO 1 hour values of B. pahangi mf at 37℃ (left panel) and room temperature (RT, right panel) across time and ivermectin (IVM) or control treatment concentrations (color-coded). P-values represent statistical differences in mf motility between DMSO and drug treatments at matched time points and temperature and were calculated using Anova/Tukey post-test and significance reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least six technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Techniques Used: Shift Assay, Control

    (A) Schematic depicting the salt assay methodology and timeline. (B) Top two bar graph panels indicate combinations of KPO 4 concentrations (10mM, 25mM, 50mM, and 100mM) and NaCl concentrations (25mM, 50mM, 100mM, 125mM, and 150mM) across the remaining figure panels at vertically aligned positions. The bottom panel shows DMSO-treated B. pahangi mf motility in the presence of different concentrations of NaCl and KPO 4 across time points. (C) The top and bottom panels show optical flow differences between DMSO and ivermectin (IVM) treated B. pahangi mf (delta motility) at varying salt combinations in the presence of 50nM (top panel) or 500nM (bottom panel) IVM. P-values representing statistical differences in mf motility between DMSO and IVM treatments were calculated using Anova/Tukey post-test and significance is reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least two technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Figure Legend Snippet: (A) Schematic depicting the salt assay methodology and timeline. (B) Top two bar graph panels indicate combinations of KPO 4 concentrations (10mM, 25mM, 50mM, and 100mM) and NaCl concentrations (25mM, 50mM, 100mM, 125mM, and 150mM) across the remaining figure panels at vertically aligned positions. The bottom panel shows DMSO-treated B. pahangi mf motility in the presence of different concentrations of NaCl and KPO 4 across time points. (C) The top and bottom panels show optical flow differences between DMSO and ivermectin (IVM) treated B. pahangi mf (delta motility) at varying salt combinations in the presence of 50nM (top panel) or 500nM (bottom panel) IVM. P-values representing statistical differences in mf motility between DMSO and IVM treatments were calculated using Anova/Tukey post-test and significance is reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least two technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Techniques Used:

    Related Articles

    other:

    Article Title: Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs
    Article Snippet: Compounds were sourced as follows: ivermectin (MP Biomedicals, LLC), diethylcarbamazine (MP Biomedicals, LLC), albendazole sulfoxide (Sigma-Aldrich), emodepside (Advanced ChemBlocks, Inc).

    Article Title: Multi-Drug Resistance Transporters and a Mechanism-Based Strategy for Assessing Risks of Pesticide Combinations to Honey Bees
    Article Snippet: Ivermectin (>95%) was purchased from MP Biomedicals, (Solon, OH), verapamil, quercetin, Rhodamine B were purchased from Sigma, a formulated solution of acetamiprid (Assail) was a gift from United Phosphorous Inc. (King of Prussia, PA), and formulated ‘Pristine’ was a gift of BASF Corp. (Research Triangle Park, NC).

    Formulation:

    Article Title: Lethal and sublethal impacts of membrane-fed ivermectin are concentration dependent in Anopheles coluzzii.
    Article Snippet: All mosquitoes were blood fed with defibrinated horse blood heated to ~ 37 °C via a feeding system using a swine intestine membrane (Hemotek, UK), at 4–5 days post-emergence and during the 12 h light photoperiod. .. An ivermectin formulation using commercially available powdered ivermectin (≥ 95%, MP BiomedicalsTM, Fisher Scientific) was prepared in dimethyl sulphoxide (DMSO) and phosphate-buffered saline (PBS). ..

    Article Title: Lethal and sublethal impacts of membrane-fed ivermectin are concentration dependent in Anopheles coluzzii
    Article Snippet: All mosquitoes were blood fed with defibrinated horse blood heated to ~ 37 °C via a feeding system using a swine intestine membrane (Hemotek, UK), at 4–5 days post-emergence and during the 12 h light photoperiod. .. An ivermectin formulation using commercially available powdered ivermectin (≥ 95%, MP BiomedicalsTM, Fisher Scientific) was prepared in dimethyl sulphoxide (DMSO) and phosphate-buffered saline (PBS). ..

    Saline:

    Article Title: Lethal and sublethal impacts of membrane-fed ivermectin are concentration dependent in Anopheles coluzzii.
    Article Snippet: All mosquitoes were blood fed with defibrinated horse blood heated to ~ 37 °C via a feeding system using a swine intestine membrane (Hemotek, UK), at 4–5 days post-emergence and during the 12 h light photoperiod. .. An ivermectin formulation using commercially available powdered ivermectin (≥ 95%, MP BiomedicalsTM, Fisher Scientific) was prepared in dimethyl sulphoxide (DMSO) and phosphate-buffered saline (PBS). ..

    Article Title: Lethal and sublethal impacts of membrane-fed ivermectin are concentration dependent in Anopheles coluzzii
    Article Snippet: All mosquitoes were blood fed with defibrinated horse blood heated to ~ 37 °C via a feeding system using a swine intestine membrane (Hemotek, UK), at 4–5 days post-emergence and during the 12 h light photoperiod. .. An ivermectin formulation using commercially available powdered ivermectin (≥ 95%, MP BiomedicalsTM, Fisher Scientific) was prepared in dimethyl sulphoxide (DMSO) and phosphate-buffered saline (PBS). ..



    Similar Products

    ivermectin  (Valiant Co Ltd)
    94
    Valiant Co Ltd ivermectin
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Ivermectin, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/bio_rxiv__64898__2026__02__12__705610-117-5-6
    Average 94 stars, based on 1 article reviews
    ivermectin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    powdered ivermectin  (Valiant Co Ltd)
    94
    Valiant Co Ltd powdered ivermectin
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Powdered Ivermectin, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/pm38755640-71-6-10
    Average 94 stars, based on 1 article reviews
    powdered ivermectin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ivermectin formulation  (Valiant Co Ltd)
    94
    Valiant Co Ltd ivermectin formulation
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Ivermectin Formulation, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/pm38755640-71-1-10
    Average 94 stars, based on 1 article reviews
    ivermectin formulation - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    pbs  (Valiant Co Ltd)
    94
    Valiant Co Ltd pbs
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Pbs, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/pm36973306-88-12-20
    Average 94 stars, based on 1 article reviews
    pbs - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    test soil ivermectin  (Valiant Co Ltd)
    94
    Valiant Co Ltd test soil ivermectin
    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with <t>ivermectin</t> (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).
    Test Soil Ivermectin, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0219600983/Ivermectin/pm22906622-61-3-11
    Average 94 stars, based on 1 article reviews
    test soil ivermectin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with ivermectin (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Journal: bioRxiv

    Article Title: Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs

    doi: 10.64898/2026.02.12.705610

    Figure Lengend Snippet: (A) Schematic depicting the methodology and time points of mf motility and viability data collection. (B) Motility dose response curves 24 hours and 48 hours after treatment with ivermectin (IVM), diethylcarbamazine (DEC), albendazole sulfoxide (AZS), and emodepside (EMO), with dashed lines showing experimental IC50 (color) and therapeutic plasma C max (black) values. Controls include mf treated with 1% DMSO and heat killed (HK) mf. (C) Viability (CellTox Green) fluorescence readings on a log 10 scale across treatment concentrations compared to DMSO and HK controls. (D) Representative brightfield (top row) and CellTox stained (bottom row) images of control and drug treated mf. (E) Motility dose response curves for drug treatment combinations. IVM treatment combined with AZS (500nM or 10µM) or DEC (15µM or 30µM), and EMO treatment combined with 15µM or 30µM DEC. Drug combination IC50s are marked as solid colored lines and IVM plasma C max values as dashed black lines. Individual drug IC50s from (B) are also shown (IVM: purple, EMO: green). Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least four technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Article Snippet: Compounds were sourced as follows: ivermectin (MP Biomedicals, LLC), diethylcarbamazine (MP Biomedicals, LLC), albendazole sulfoxide (Sigma-Aldrich), emodepside (Advanced ChemBlocks, Inc).

    Techniques: Clinical Proteomics, CellTox Assay, Fluorescence, Staining, Control

    (A) Schematic showing methodology and timeline for mf temperature shift assay. (B) Mean motility, scaled to DMSO 1 hour values of B. pahangi mf at 37℃ (left panel) and room temperature (RT, right panel) across time and ivermectin (IVM) or control treatment concentrations (color-coded). P-values represent statistical differences in mf motility between DMSO and drug treatments at matched time points and temperature and were calculated using Anova/Tukey post-test and significance reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least six technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Journal: bioRxiv

    Article Title: Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs

    doi: 10.64898/2026.02.12.705610

    Figure Lengend Snippet: (A) Schematic showing methodology and timeline for mf temperature shift assay. (B) Mean motility, scaled to DMSO 1 hour values of B. pahangi mf at 37℃ (left panel) and room temperature (RT, right panel) across time and ivermectin (IVM) or control treatment concentrations (color-coded). P-values represent statistical differences in mf motility between DMSO and drug treatments at matched time points and temperature and were calculated using Anova/Tukey post-test and significance reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least six technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Article Snippet: Compounds were sourced as follows: ivermectin (MP Biomedicals, LLC), diethylcarbamazine (MP Biomedicals, LLC), albendazole sulfoxide (Sigma-Aldrich), emodepside (Advanced ChemBlocks, Inc).

    Techniques: Shift Assay, Control

    (A) Schematic depicting the salt assay methodology and timeline. (B) Top two bar graph panels indicate combinations of KPO 4 concentrations (10mM, 25mM, 50mM, and 100mM) and NaCl concentrations (25mM, 50mM, 100mM, 125mM, and 150mM) across the remaining figure panels at vertically aligned positions. The bottom panel shows DMSO-treated B. pahangi mf motility in the presence of different concentrations of NaCl and KPO 4 across time points. (C) The top and bottom panels show optical flow differences between DMSO and ivermectin (IVM) treated B. pahangi mf (delta motility) at varying salt combinations in the presence of 50nM (top panel) or 500nM (bottom panel) IVM. P-values representing statistical differences in mf motility between DMSO and IVM treatments were calculated using Anova/Tukey post-test and significance is reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least two technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Journal: bioRxiv

    Article Title: Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs

    doi: 10.64898/2026.02.12.705610

    Figure Lengend Snippet: (A) Schematic depicting the salt assay methodology and timeline. (B) Top two bar graph panels indicate combinations of KPO 4 concentrations (10mM, 25mM, 50mM, and 100mM) and NaCl concentrations (25mM, 50mM, 100mM, 125mM, and 150mM) across the remaining figure panels at vertically aligned positions. The bottom panel shows DMSO-treated B. pahangi mf motility in the presence of different concentrations of NaCl and KPO 4 across time points. (C) The top and bottom panels show optical flow differences between DMSO and ivermectin (IVM) treated B. pahangi mf (delta motility) at varying salt combinations in the presence of 50nM (top panel) or 500nM (bottom panel) IVM. P-values representing statistical differences in mf motility between DMSO and IVM treatments were calculated using Anova/Tukey post-test and significance is reported as follows, * : p<0.05, ** : p<0.01, *** : p<0.001. Each plot point represents measurements for a plate well containing 1000 mf; each condition was performed across at least two technical replicates (wells) per experiment and each experiment was repeated for at least three biological replicates (parasite cohorts).

    Article Snippet: Compounds were sourced as follows: ivermectin (MP Biomedicals, LLC), diethylcarbamazine (MP Biomedicals, LLC), albendazole sulfoxide (Sigma-Aldrich), emodepside (Advanced ChemBlocks, Inc).

    Techniques: